The company holds exclusive licenses for cord blood banking in Beijing (since 2002), Guangdong (since 2006), and Zhejiang (since 2010). This monopoly position in three major Chinese provinces with 1.8 million annual births provides significant market protection and recurring revenue potential from subscription-based cord blood storage services.
Cyborg Score Rationale
The company faces significant governance and financial transparency concerns. Auditors have been unable to locate the USD one billion cash reserve claimed in the 2022 annual report, finding only USD 444 thousand in bank accounts as of June 2023. Stock performance has deteriorated substantially with a 40% one-year decline.
Top Insights
Holds exclusive monopoly licenses for cord blood banking across three major Chinese provinces, a rare and valuable competitive moat
Significant corporate governance and financial transparency concerns with disputed cash reserves and unexplained asset transfers
Stock trading on OTC markets (delisted from major exchanges) with severe liquidity and price weakness
Court action by Jersey-based liquidators reveals operational access restrictions and internal cooperation failures
Named Competitors
Alternative Private Cord Blood Banks — Regional cord blood banking operators in non-monopoly provinces
Regenerative Medicine Services — Broader cellular therapy and stem cell alternatives
Recent Developments
(Feb 2026) Stock trading at $0.75 with -31.82% daily decline and -40% annual decline
(Jun 2023) Only USD 444 thousand located in verified bank accounts versus claimed USD 1 billion
(2023) Ongoing litigation regarding asset transfers and governance transparency
Open the full interactive Global Cord Blood Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.